Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 2/20 | 0.53 |
| ▸ | TNKS | O95271 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GPR3 | P46089 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | IDE | P14735 | 1/20 | 0.53 |
| ▸ | MPI | P34949 | 1/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.53 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415434 | 1.00 | KDM4E (1.00) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL29950909 | 0.90 | KDM4E (1.00) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL3985154 | 0.85 | KDM4E (0.74) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL9354766 | 0.85 | KDM4E (0.74) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL8678798 | 0.85 | KDM4E (0.74) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL31298181 | 0.85 | KDM4E (0.74) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL4895906 | 0.84 | KDM4E (0.72) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL1620204 | 0.84 | KDM4E (0.72) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL30880425 | 0.84 | KDM4E (0.72) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL15067394 | 0.84 | KDM4E (0.72) | KDM4ETDP1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | claimed |
| US-11559474-B2 | Hair lightening compositions and methods of use | L'OREAL (FR) | 2023-01-24 | — | — | US | disclosed |
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | disclosed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | disclosed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | disclosed |
| US-20090028807-A1 | COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION | L'OREAL (FR) | 2009-01-29 | — | — | US | disclosed |
| US-5908932-A | Certain pyrroloquinolinones; a new class of GABA brain receptor | NEUROGEN CORPORATION (US) | 1999-06-01 | — | — | US | disclosed |
| US-5604235-A | DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, BENZODIAZEPINE OVERDOSE; ENHANCEMENT OF MEMORY | NEUROGEN CORPORATION (US) | 1997-02-18 | — | — | US | disclosed |
| WO-1994026741-A1 | CERTAIN PYRROLOQUINOLINONES; A NEW CLASS OF GABE BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1994-11-24 | — | — | WO | disclosed |
| US-5318963-A | Heterocyclic hydrazide derivatives of monocyclic β-lactam antibiotics | E. R. SQUIBB & SONS, INC. (US) | 1994-06-07 | — | — | US | disclosed |
| US-5243049-A | Gamma-aminobutyric acid antagonist | NEUROGEN CORPORATION (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0420069-A2 | Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics | E.R. SQUIBB & SONS, INC. (US) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | KDM4E 2504/4885TDP1 3475/4885MEN1 2029/4885 |
| US-20090028807-A1 | COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION | CUTA, SYMPK, TPRKB | KDM4E 1615/4885TDP1 2239/4885MEN1 452/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | KDM4E 1109/4885TDP1 3912/4885MEN1 748/4885 |
| US-11559474-B2 | Hair lightening compositions and methods of use | TYR, ALAD, CYBA | KDM4E 2585/4885TDP1 2687/4885MEN1 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.